

Comparison of the Ecological Footprints of administering Salbutamol by Metered-Dose Inhaler and by Nebulization in Emergency Treatment of Acute Asthma

Running head: Environmental impact of asthma emergency treatment

Simon Berthelot MD MSc^{1,2}: simon.berthelot@fmed.ulaval.ca

Jean-François Ménard³: jean-francois.menard@polymtl.ca

Guillaume Bélanger-Chabot⁴ PhD: guillaume.belanger-chabot@chm.ulaval.ca

Gabriela Arias Garcia⁴: gabi950706@gmail.com

Diego Mantovani⁵ PhD: diego.mantovani@crchudequebec.ulaval.ca

Chantale Simard B. Pharm. PhD^{6,7}: chantale.simard@pha.ulaval.ca

Jason R. Guertin PhD^{2,8,9}: jason.guertin@fmed.ulaval.ca

Tania Marx MD PhD¹⁰: tania.marx@univ-fcomte.fr

Ariane Bluteau MSc²: ariane.bluteau@crchudequebec.ulaval.ca

1. Département de médecine de famille et de médecine d'urgence, Université Laval, Québec, QC, Canada
2. Axe Santé des populations et Pratiques optimales en santé, Centre de recherche du CHU de Québec-Université Laval, Québec, QC, Canada
3. CIRAIQ – Polytechnique Montréal, Montréal, QC, Canada
4. Département de chimie, Université Laval, Québec, QC, Canada
5. Axe Médecine régénératrice, Centre de recherche du CHU de Québec-Université Laval, Québec, QC, Canada
6. Centre de recherche, Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval, Québec, QC, Canada
7. Faculté de pharmacie, Université Laval, Québec, QC, Canada
8. Département de médecine sociale et préventive, Université Laval, Québec, QC, Canada
9. Centre de recherche en organogénèse expérimentale de l'Université Laval/LOEX, Québec, QC, Canada
10. Département de médecine d'urgence, Centre Hospitalier Universitaire de Besançon, Besançon, France

Corresponding author :

Dr. Simon Berthelot

2705 Boul. Laurier

Québec City, Qc

Canada

G1V 4G2

(418) 525-4444; 70553

ORCID : 0000-0002-0372-0586

simon.berthelot@fmed.ulaval.ca

Ethics approval :

Not applicable due to the study design (life cycle assessment).

Presentation :

This work was presented on June 4th at the 2024 Canadian Association of Emergency Physicians Conference.

Financial support:

This study was funded by a grant from the “Association des spécialistes en médecine d’urgence du Québec”.

Author contributions :

SB and JRG designed the study. SB and AB supervised its conduct. AB, TM, CS and SB collected the inventory data. SB and JFM carried out the life cycle assessment. SB drafted the initial manuscript. All authors proofread the manuscript and approved its submitted version. SB assumes responsibility for the integrity of the data used in this study and the accuracy of its analysis.

Conflict of interest disclosure:

The authors have no conflict of interest to disclose.

Acknowledgement:

The authors thank Ms. Laurie Ouellet for granting permission to use her figure illustrating the life cycle.

Word counts

Abstract: 242

Text: 2311

TAKE-HOME POINTS

Study question

What is the ecological footprint of metered-dose inhalers compared to nebulization for administering salbutamol when treating a patient with acute asthma in the emergency department?

Results

Nebulization was found to have half the carbon footprint of 1 MDI administration and one quarter of 3 MDI administrations.

Interpretation

Implementing low-emission treatment protocols for acute asthma should be one of many avenues to explore to achieve net-zero greenhouse gas emissions in healthcare services.

ABSTRACT

Background

The scientific evidence indicates little or no difference in the effectiveness or cost of using of metered-dose inhalers (MDIs) versus nebulization to treat acute asthma in the emergency department (ED). However, the use of MDIs raises questions of environmental impact. The objective of this study was to compare the carbon footprint of salbutamol administered by MDI versus nebulization.

Methods

Applying a life cycle assessment methodology, we quantified the resources extracted and pollutants emitted by each therapeutic option, from the factory production of medication and equipment to disposal by incineration. Each piece of inventory data was then translated into CO₂-equivalent emissions (CO₂eq) using the IPCC2021/GWP100 method. Results were estimated for the administration of 1 and 3 treatments of 800 µg of salbutamol by MDI and 5 mg by nebulization (standard doses for adults and children ≥ 24 kg) and compared to the use of a subcompact car.

Results

One and three ED-administered treatments with salbutamol emit respectively 1.9 and 4.0 kg of CO₂eq via MDI versus 0.9 and 1.0 kg via nebulization, which corresponds to 5.5 km and 11.6 km and to 2.7 km and 2.8 km traveled in a subcompact car. Each series of 8 inhalations from an MDI releases 1.1 kg of CO₂eq due to emission of the hydrofluoroalkane propellant.

Interpretation

Considering the absence or minimal difference in clinical effectiveness, this study suggests that nebulization may be a more eco-efficient administration route than MDIs in the emergency treatment of asthma.

Trail registration: N/A

Key words:

acute asthma; emergency department; ecological footprint; life cycle assessment.

Abbreviations:

ED: emergency department

CO₂eq: CO₂ equivalents

MDI: metered-dose inhalers

COPD: chronic obstructive pulmonary disease

HFA: hydrofluoroalkane

DALY: disability-adjusted life-year

MJ: megajoule

PDF·m²·year: potentially disappeared fraction of species over square meter years

IPCC2021 GWP100: Intergovernmental Panel on Climate Change for 2021 – Global Warming

Potential for 100-year period

DPI: dry powder inhaler

INTRODUCTION

Healthcare services are responsible for 4.6% of greenhouse gas emissions worldwide ¹. The USA and Canada rank first and third, respectively, in per capita healthcare-related emissions of CO₂ equivalents (CO₂eq) ¹. Increasing emissions of greenhouse gases contribute to global warming, of which the negative impact on human health includes an increase in heat-related illnesses and respiratory problems as well as wider spread of infectious diseases ².

The use of metered-dose inhalers (MDIs) to administer bronchodilators (e.g., salbutamol) is considered a significant source of health-service-associated greenhouse gas emissions ³. It has been estimated that in the United Kingdom, up to 13% of such emissions result from the use of MDIs to treat asthma or chronic obstructive pulmonary disease (COPD). The main greenhouse gas emitted from these devices is the hydrofluoroalkane (HFA) propellant. Some HFAs have atmospheric warming potentials up to 3000 times that of CO₂ ^{4,5}. Consequently, replacing MDIs with HFA-free administration methods is regarded as desirable whenever possible. However, MDI use has become the standard of care in many emergency departments ^{6,7}. Administration of a bronchodilator in the form of fine droplets is the main therapeutic alternative in the hospital setting. This mode, known as nebulization, is said to have equivalent clinical effectiveness ⁸. To our knowledge, its environmental impact has never been evaluated and compared to that of MDIs ⁵.

The objective of this study was to compare the environmental footprints of MDI and nebulization when used to administer salbutamol to adults in emergency departments.

METHODS

Design and Setting

This is an observational study comparing MDIs and nebulization as methods of administering salbutamol to asthmatic patients in emergency departments, using a life cycle assessment methodology to calculate the "cradle to grave" environmental footprints (Figure 1). The study was conducted during fiscal year 2022-23 at the CHU de Québec-Université Laval (hereafter the CHU), an academic institution that manages five EDs located throughout Québec City (Canada) and receiving more than 240,000 visits annually.

Figure 1. Components of life cycle assessment from cradle to grave




Figure printed with permission from Ms. Laurie Ouellet

Life cycle assessment

We evaluated an MDI (100 µg of salbutamol/dose, 200 doses) and a nebulization ampoule (5 mg/mL, 10 mL), both products manufactured by GSK. An MDI is for single-patient use, whereas multiple patients can be treated with a single nebulization ampoule.

The assessment followed ISO standards 14040 and 14044^{9,10} and consisted of 4 phases:

1 – Definition of the goal, scope, and functional unit

We compared 1 and 3 administrations of a standard dose of salbutamol in the ED for adults and children weighing ≥ 24 kg, namely 800 µg (8 puffs) via MDI and 5 mg (1 ml) via nebulization (functional unit). The life cycle assessment included production, packaging, transportation, use in the ED, and incineration, assuming all material disposal takes place at the hospital. We considered MDI treatments with a reusable plastic spacer or a single-use cardboard spacer, as well as all the reusable material (nebulizing cup, plastic tubing, oxygen mask) required for nebulization.

2 – Life cycle inventory

We decomposed the life cycles of the 2 therapeutic options to identify all emissions and extractions within the system boundaries. In addition to the product monographs, we obtained the inventory data for all components of the MDI, plastic and cardboard spacers, nebulization ampoule and materials using attenuated total reflectance infrared spectroscopy, which provides detailed information about the molecular composition of a product. The composition of the MDI canister gas was analyzed using multinuclear nuclear magnetic resonance and gas-phase infrared spectroscopies. The methods for identifying the volatile components are described in e-Appendix 1. The production plants were located using procurement information obtained from our institution. The road distance to the biomedical waste management company used by the CHU (Stericycle) was determined. The complete life cycles were modeled using the openLCA software and the ecoinvent life

cycle inventory database (version 3.9.1) and adapting some processes to the [name of the region] context.

3 – Impact assessment and outcome measures

The inventoried emissions and extractions were translated into environmental indicators in the following impact categories: i) *Climate change*, in kg of CO₂ equivalent emissions (CO₂eq); ii) *Human health*, in disability-adjusted life-year (DALY) loss; iii) *Fossil resources use*, in megajoules (MJ) deprived; and iv) *Ecosystem quality*, in potentially disappeared fraction of species (PDF) over square meter years (PDF·m²·year). The human health and ecosystem quality indicators aggregate a series of intermediate effects of the production, use, and disposal of asthma treatment products. The inventory data were converted into impact units using the validated assessment method IPCC2021 GWP100 for *Climate change* and the IMPACT World+ method for the other impact categories.

4 – Interpretation of results

The indicator results were interpreted relative to the functional units for 1 or 3 administrations, which are common initial prescriptions for asthma treatment in many ED protocols. Hotspots were identified, that is, the life cycle elements having the highest contribution to the indicator.

Alternative scenarios and extrapolations

Patients discharged from the CHU EDs are often allowed to keep the MDI for use at home. We considered this alternative scenario in the model by assuming that all such MDIs were emptied and ended up in the same incinerator as if they had been left in the ED.

We also estimated the annual environmental footprint of the asthma treatments based on medication consumption recorded at the CHU during 2022–2023. Since it was not possible to

retrace the number of administrations and the dosages for each patient treated with an MDI, we assumed a minimum of 3 administrations of 800 µg (8 inhalations) for each MDI delivered by the pharmacy to the ED during the study period.

Statistical analysis

We report the results as point estimates and stacked bar charts in accordance with the standards used for life cycle assessment reporting. To account for the uncertainties of the proxies used in the inventory, we conducted a Monte Carlo simulation analysis with 1,000 iterations, from which we calculated point estimates for each indicator, differences between salbutamol administration modes, and 95% confidence intervals. All analyses were performed using openLCA (GreenDelta, version 2.0.4).

RESULTS

Life cycle inventories

The life cycle inventories of salbutamol treatments using MDIs and nebulization are reported in Table 1. The HFA used in the inhaler is 1,1,1,2-tetrafluoroethane, a gas having a global warming potential 1,500 times that of CO₂.

The distances of the production plant and the incinerator (for both salbutamol administration methods) from the CHU were respectively 1605 km and 1813 km.

TABLE 1. Life cycle inventories of salbutamol administration in emergency departments using metered-dose inhalers and nebulization

COMPONENT	Mass (g)	NMR/ FT-IR Spectroscopy	EcolInvent 3.9 flow
METERED-DOSE INHALER			
<i>Chemical ingredients</i>			
Active substance	0.02	Salbutamol sulfate	Salbutamol sulfate
Norflurane Propellant	17.3	1,1,1,2-Tetrafluoroethane	Refrigerant R134a
Surfactant	0.11	Water	Water, ultrapure
<i>Metering valve</i>			
Ferrule	1.1	Aluminium	Aluminium, primary, ingot
Gasket	0.13	N/A	N/A
Compression spring	0.09	Steel	Steel, unalloyed
Tank seal	0.13	N/A	N/A
Stem	0.41	Polyoxyethylene	
Diaphragm	0.39	Polyoxyethylene	
Bottle emptier	0.76	Polyoxyethylene	
<i>Actuator</i>			
Actuator stem	8.62	Polypropylene	Polypropylene, granulate
Actuator safety cap	1.2	Polypropylene	Polypropylene, granulate
<i>Canister</i>			
Metal container	7.64	95% Aluminium et 5% Magnesium	Aluminum alloy, AlMg3
<i>Packaging</i>			
Drug Label	0.14	Cellulose acetate	Printed paper, offset
Drug information leaflet	5.54	Cellulose acetate	Printed paper, offset
Primary packaging	5.15	Cellulose acetate*	Solid bleached and unbleached board carton
Shipping container	2.39	Cellulose acetate	Corrugated board box
Safety tape	0.01	Cellulose acetate with dye	Paper, melamine impregnated
Safety seals	0.02	Polypropylene	Polypropylene, granulate
Coded Safety seal	0.004	Polyvinylchloride	Polyvinylchloride, bulk polymerized
PLASTIC SPACER			
Mouthpiece	12.41	Polyester resine	Maleic unsaturated polyester resin
Internal valve	2.99	Silicon rubber	Silicone / poly dimethyl siloxane
Internal membrane	1.56	Polypropylene	Polypropylene, granulate
External air valve	1.64	Polyester resin	Maleic unsaturated polyester resin
Opaque side	11.25	Polypropylene	Polypropylene, granulate
Transparent side	15.42	Polypropylene	Polypropylene, granulate
Mouthpiece cap	3.16	Polypropylene	Polypropylene, granulate
Packaging	2.8	Polyethylene	Polyethylene, high density, granulate
CARDBOARD SPACER			
Internal part	12.77	Papier	Containerboard, unspecified
External part	24.06	Polyvinyl chloride carbonylated 2%	Polyvinylchloride, bulk Polymerised
Plastic film	0.21	Polypropylene	Polypropylene, granulate
Packaging	2.06	Polyethylene	Packaging film, low density Polyethylene
User instructions	9.03	Papier	Printed paper, offset
NEBULIZATION			
<i>Chemical ingredients</i>			
Active substance	0.05	salbutamol sulfate	salbutamol sulfate
Surfactant 1	0.01	water	water, ultrapure

	Surfactant 2	0.05	sulfuric acid	sulfuric acid
	Surfactant 3	0.002	benzalkonium Chloride	benzalkonium Chloride
<i>Container</i>				
	Vial	38.5	Glass	packaging glass, brown
	Cap	1.75	polypropylene	polypropylene, granulate
	Packaging			
	Drug Label	0.26	polypropylene	polypropylene, granulate
	Drug information leaflet	2.15	Cellulose acetate	printed paper, offset containerboard, unspecified
	Primary packaging	3.34	Cellulose acetate	
	Safety tape	0.79	polyethylene	packaging film, low density polyethylene
<i>Saline tube</i>				
	Plastic tube	2.27	polyethylene	polyethylene terephthalate, granulate, bottle grade
	Water	3.00	N/A	Water, ultrapure
	Sodium salt	0.03	N/A	sodium chloride, powder
<i>Nebulizing cup</i>				
	Plastic packaging	1.14	polyethylene	packaging film, low density polyethylene
	Information leaflet	1.11	paper	printed paper, offset
	cap	6.68	polypropylene	polypropylene, granulate
	Drug mixing chamber	7.02	polystyrene (+/- chlore)	polystyrene, general purpose
	Internal component of the reservoir	1.68	polystyrene (+/- chlore)	polystyrene, general purpose
<i>Tubing</i>				
	Plastic tube	41.36	polyester, isophthalic acid (Vinyl)	isophthalic acid based unsaturated polyester resin
	Packaging	1.80	polyethylene	Polyethylene, high density, granulate
	Information leaflet	1.12	paper	Printed paper, offset
<i>Adult Oxygen Mask</i>				
	Packaging	2.96	polyethylene	packaging film, low density polyethylene
	Information leaflet	0.29	paper	printed paper, offset
	Tube connector	2.24	polypropylene	polypropylene, granulate
	Mouthpiece	24.54	poly butylene terephthalate	polybutylene terephthalate_model
	Metal hook	0.55	aluminum	aluminium, primary, ingot
	safety rubber	1.20	polyamide	nylon 6-6
	Tubing	40.78	polyester (polybutylene terephthalate)	polybutylene terephthalate_model

Impact categories

The environmental footprint of the two methods is reported per impact category for 1 and 3 administrations in Tables 2 and 3, and e-Figures 1 to 4. The *Climate change* indicator hotspot for MDIs is HFA emission. Their carbon footprint is thus linked to their use: each series of 8 inhalations emits 1.1 kg of CO₂eq as 1,1,1,2-tetrafluoroethane. This emission is also a notable contributor to the other indicators (especially in the case of 3 series) but MDI and

spacer production and disposal (of the plastic spacer more than the cardboard) are also contributors. For nebulization, cup and mask production and disposal are hotspots for all indicators. Since these devices are reusable, indicator results do not increase much with the number of administrations. The results also indicate that although the single-use cardboard spacer leaves a smaller footprint than the plastic spacer after 1 administration, this difference diminishes or reverses in favor of the plastic spacer after 3 administrations.

TABLE 2. Climate change and human health indicators for salbutamol administration in the emergency department

# admin	Mode of administration	Climate change (kg CO ₂ eq)		Human health (DALY)	
		Point estimate *	Median (IQR)**	Point estimate X 10 ⁻⁶	Median (IQR) X 10 ⁻⁶
1	MDI/plastic spacer	1.89	1.91 (1.80; 2.05)	4.1	1.7 (-64.3; 70.0)
	MDI/cardboard spacer	1.66	1.70 (1.58; 1.83)	3.3	2.1 (-97.8; 99.3)
	Nebulization	0.95	1.10 (1.06; 1.14)	3.9	13.0 (-191.2; 185.5)
3	MDI/plastic spacer	4.00	4.05 (3.69; 4.43)	6.0	5.8 (-55.6; 74.9)
	MDI/cardboard spacer	3.96	4.00 (3.66; 4.38)	6.0	5.7 (-182.0; 193.7)
	Nebulization	0.99	1.13 (1.10; 1.18)	4.0	2.7 (-186.0; 206.1)

*Point estimates obtained from impact evaluation of the life cycle assessment methodology

**Medians and interquartile ranges (IQR) estimated using a Monte Carlo simulation (1,000 iterations)

#admin: number of administrations in the emergency department

MDI: metered-dose inhaler; CO₂eq: CO₂ equivalent emissions; DALY: disability-adjusted life-year.

TABLE 3. Biodiversity and fossil resource use indicators for salbutamol administration in the emergency department

# admin	Mode of administration	Ecosystem quality (PDF·m ² ·year)		Fossil resources (Megajoules deprived)	
		Point estimate*	Median (IQR)**	Point estimate	Median (IQR)
1	MDI/plastic spacer	0.95	0.96 (0.70; 1.28)	9.44	9.75 (9.49; 10.04)
	MDI/ cardboard spacer	0.76	0.78 (0.50; 1.09)	5.93	6.20 (5.98; 6.39)
	Nebulization	0.97	1.12 (0.33; 1.94)	14.00	16.77 (16.08; 17.53)
3	MDI/plastic spacer	1.36	1.42 (1.12; 1.68)	9.44	9.73 (9.46; 10.00)
	MDI/ cardboard spacer	1.41	1.47 (0.95; 1.99)	8.64	9.02 (8.72; 9.31)
	Nebulization	1.01	1.25 (0.36; 2.10)	14.60	17.38 (16.63; 18.13)

*Point estimates obtained from impact evaluation of the life cycle assessment methodology

**Medians and interquartile ranges (IQR) estimated using a Monte Carlo simulation (1,000 iterations)

#admin: number of administrations in the emergency department

MDI: metered-dose inhaler; PDF·m²·year: Potentially disappeared fraction of species over square meter years.

Table 4 displays the median and 95% confidence interval of the difference between MDI and nebulization for each impact category. The *Climate change* impact is significantly greater for MDI than for nebulization, and this difference is greater for 3 administrations, reaching up to 2.9 kg CO₂eq. The two salbutamol treatment methods are indistinguishable in the *Human health* category for 1 and 3 administrations. Nebulization has a greater negative impact on ecosystem quality after 1 administration, but the difference between the two methods is reversed after 3 administrations, as MDIs result in a greater loss of biodiversity. Nebulizing shows significantly higher impact on *Fossil resources use* than MDI at both 1 and 3 administrations.

TABLE 4. Differences between administering salbutamol via metered-dose inhaler and nebulization in the emergency department: environmental indicators

#admin	Modes	Climate change (kg CO ₂ eq)	Human health (DALY) X 10 ⁻⁵	Ecosystem quality (PDF·m ² ·year)	Fossil resources (MJ deprived)
1	MDI/plastic spacer minus Nebul	0.85 (0.84 to 0.86)*	0.84 (-0.31 to 1.99)	-0.12 (-0.17 to -0.07)	-6.99 (-7.06 to -6.92)
	MDI/cardboard spacer minus Nebul	0.61 (0.60 to 0.62)	-1.05 (-2.37 to 0.26)	-0.37 (-0.43 to -0.32)	-10.58 (-10.65 to -10.51)
3	MDI/plastic spacer minus Nebul	2.92 (2.89 to 2.96)	-0.93 (-2.10 to 0.25)	0.21 (0.15 to 0.26)	-7.68 (-7.75 to -7.61)
	MDI/cardboard spacer minus Nebul	2.91 (2.88 to 2.95)	-0.20 (-1.85 to 1.45)	0.30 (0.25 to 0.35)	-8.38 (-8.45 to -8.31)

*Difference (95% Confidence Interval) between the treatment options estimated using a Monte Carlo simulation (1,000 iterations)

#admin: number of administrations

MDI: metered-dose inhaler; CO₂eq: CO₂ equivalent emissions;

DALY: disability-adjusted life-year;

Nebul: nebulization

PDF·m²·year: Potentially disappeared fraction of species over square meter years

Metered-dose inhaler left to the patient for home use

The environmental footprint of the scenario in which the patient upon discharge is allowed to keep the MDI for use at home is reported in e-Table 1. For all categories, the impact of this scenario is lower than disposal of the MDI at the hospital. While the contribution of HFA emission continues to increase, the contribution of MDI production and disposal is spread

over 200 inhalations instead of 8 or 24 (1 or 3 administrations) per functional unit. The previously observed differences between MDIs and nebulization for all indicators do not change significantly under this scenario. We estimated a difference of 2.5–2.6 kg CO₂eq between MDI and nebulization for 3 treatments, with no significant differences noted in other categories of impact.

One-year ecological footprint

In fiscal year 2022–2023, 4,815 MDIs and 233 nebulizer ampoules were dispensed in the 5 EDs associated with the CHU. The corresponding annual environmental footprint is reported by impact category in Table 5, based on each patient receiving 3 administrations of salbutamol while in the ED. An emission of 19,260 kg of CO₂ equivalent is attributable to the use of MDIs. If all patients had received nebulization, this emission would have been 14,416 kg lower, and losses of 0.93 x 10⁻² DALY and 1,606 PDF·m²·year would have been avoided, but an additional 25,984 MJ in fossil resources would have been consumed. The 14,416 kg of CO₂eq emissions is equivalent to driving 84,800 kilometers in a subcompact car or 19 trips from New York to Los Angeles.

TABLE 5. Extrapolation of the Ecological Footprint of Salbutamol Administration via Metered-Dose Inhaler and Nebulization According to Medication Consumption Recorded at the CHU in Fiscal Year 2022-23

Administration mode	Number of patients	Climate change (kg CO₂ eq)	Human health (DALY) X 10⁻²	Use of fossil resources (MJ)	Ecosystem quality (PDF.m².year)
MDI/plastic spacer	4815*	19,260	2.89	45,454	6,548
Nebulization	78**	77	0.03	1,139	79
If only Nebulization had been used	4893	4,844	1.96	71,438	4,941
Potentially saved if only Nebulization used		14,416	0.93	-25,984	1,606

*Represents the number of salbutamol metered-dose inhalers served in the emergency department in 2022-23.
**Represents the number of nebulization ampoules (n=233, 5 mg/ml) consumed in the emergency department in 2022-23 divided by 3 assuming all patients received 3 treatments of 5 mg of salbutamol (15 mg in total).
MDI: Metered-Dose Inhaler; CO₂eq: CO₂ equivalent emissions; DALY: Disability-Adjusted Life Year;
PDF.m².year: Potentially Disappeared Fraction of species per square meter per year

DISCUSSION

In this product/process life cycle assessment, we examined ED treatment of acute asthma using salbutamol administration via MDIs versus nebulization. Nebulization was found to have half the carbon footprint of 1 MDI administration and one quarter of 3 MDI administrations. The two methods are indistinguishable in the *Human health* category for 1 and 3 administrations, and in the *Ecosystem quality* category for 1 administration but not 3, at which the MDI had a significantly higher impact. Nebulizing shows significantly higher impact on *Fossil resources use* for 1 or 3 MDI administrations. When scaled to the 5,000 patients treated annually for asthma in the EDs of the institution where this research was conducted, nearly 20,000 kg CO₂ equivalent emissions would be attributable to the use of MDIs and nearly 15,000 kg would be avoided by prescribing nebulization.

Previous literature

To our knowledge, this is the first study comparing the environmental footprint of MDIs and nebulization in the ED. Goulet et al. compared HFA-based MDIs to a portable nebulizer device for use at home by patients with COPD¹¹. Comparisons with their study should be made carefully since: 1) a different functional unit was used (200 µg of Albuterol by MDI and 3 mg by nebulizer); 2) the nebulizer device studied is not used in the ED; and 3) MDI administration was modeled alone without a spacer. Still, the authors calculated a carbon footprint 2 to 3 times higher for one dose with an MDI compared to one dose with a nebulizer, whereas we estimated that one emergency treatment with an MDI has twice the carbon

footprint of nebulization. In absolute numbers, their CO₂eq associated with MDI use appears disproportionately low (0.097 kg CO₂eq for 2 inhalations) compared to our estimates (1.89 kg CO₂eq for 8 inhalations). However, the Goulet et al. model contained 6.7 g of HFA compared to 17.3 g used in our calculations. Their method of estimating the quantity of HFA is not described in detail, whereas our approach is reproducible and aligns with the quantities estimated another study that focused on gas kinetics associated with pressurized MDIs ¹².

We also modeled the scenario in which the patient uses the MDI at home, which was found to lead to a lower carbon footprint. However, dry powder inhalers (DPI), which can be used by patients aged 6 and above ¹³, have been found comparable in efficacy ¹⁴ and cost ¹⁵ to MDIs and to have a carbon footprint 20-30 times smaller ¹⁶. If DPIs are in fact usable at home in the same manner as bronchodilators, then discarding MDIs after use in the ED would become the approach having the least impact as a source of greenhouse gas emission.

Future direction

This study of a specific aspect of the environmental footprint of healthcare systems suggests that nebulization is a more eco-efficient method of administering bronchodilators in EDs that receive many patients needing such treatments. However, particularly in children, this method has been associated with more side effects and longer ED stays ⁸. Further research is needed to determine if the use of DPIs is effective and safe as ED treatment of mild to moderate acute asthma, which would allow nebulization to be reserved for the most severe cases.

Limitations

Among the limitations of this study, we must mention our creation of the life cycle inventories without access to industry information. However, the method used is scientifically robust and reproducible, and we are confident that the resulting analysis adequately estimates the differences in environmental footprint between MDI use and nebulization. Our results might have differed if other inventory databases and impact assessment methods had been used. However, the ecoinvent database is one of the most widely used in the world, and processes were adapted to the [name of the region] context when this was relevant. The CO₂eq assessment method is that proposed by the Intergovernmental Panel on Climate Change, a widely recognized international organization created under the auspices of the UN to assess risks related to climate change. We believe that this choice of tools makes our analysis as robust and credible as presently possible. Finally, to estimate the one-year environmental footprint, we assumed that patients received their 3 MDI treatments at 20-minute intervals, since this is the protocolized prescription for asthma treatment in the CHU emergency departments. Since a significant number of patients end up receiving more than 3 treatments, our extrapolations are likely underestimates of the real impact.

CONCLUSION

Acute asthma is one of the most frequent conditions treated in emergency departments. The administration of salbutamol for this purpose usually involves the use of an MDI, which has a significant environmental footprint. Our study shows that administering salbutamol by nebulization has a smaller footprint. Given that more and more governments around the world are committed to providing healthcare services with net-zero greenhouse gas emissions over the coming decades, implementing low-emission ED treatment protocols for acute asthma should be one of many avenues to explore to achieve this goal.

REFERENCES

1. Watts N, Amann M, Arnell N, et al. The 2019 report of The Lancet Countdown on health and climate change: ensuring that the health of a child born today is not defined by a changing climate. *Lancet*. 2019;394(10211):1836-1878.
2. Romanello M, McGushin A, Di Napoli C, et al. The 2021 report of the Lancet Countdown on health and climate change: code red for a healthy future. *Lancet*. 2021;398(10311):1619-1662.
3. Karliner J, Slotterback S, Boyd R, Ashby B, Steele K. Health care's climate footprint: How the Health Sector Contributes to the Global Climate Crisis and Opportunities for Action. <https://noharm-uscanada.org/ClimateFootprintReport>. Published 2019. Accessed April 28, 2021.
4. Starup-Hansen J, Dunne H, Sadler J, Jones A, Okorie M. Climate change in healthcare: Exploring the potential role of inhaler prescribing. *Pharmacol Res Perspect*. 2020;8(6):e00675.
5. Wilkinson A, Woodcock A. The environmental impact of inhalers for asthma: A green challenge and a golden opportunity. *Br J Clin Pharmacol*. 2022;88(7):3016-3022.
6. TREKK. Bottom line recommendations: Asthma. https://trekk.ca/system/assets/attachments/439/original/2020-01-23_Asthma_BLR_v_1.5.pdf?1579801436. Accessed February 10, 2023.
7. Abaya R, Delgado EM, Scarfone RJ, et al. Improving efficiency of pediatric emergency asthma treatment by using metered dose inhaler. *The Journal of asthma : official journal of the Association for the Care of Asthma*. 2019;56(10):1079-1086.
8. Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. *Cochrane database of systematic reviews*. 2013(9):CD000052.
9. Organisation internationale de normalisation. ISO14040:2006(fr) Management environnemental — Analyse du cycle de vie — Principes et cadre. <https://www.iso.org/obp/ui/fr/#iso:std:iso:14040:ed-2:v1:fr>. Published 2006. Accessed March 23, 2021.
10. Organisation internationale de normalisation. ISO 14044:2006(fr) Management environnemental — Analyse du cycle de vie — Exigences et lignes directrices. <https://www.iso.org/obp/ui/fr/#iso:std:iso:14044:ed-1:v1:fr>. Published 2006. Accessed March 23, 2021.
11. Goulet B, Olson L, Mayer BK. A Comparative Life Cycle Assessment between a Metered Dose Inhaler and Electric Nebulizer. *Sustainability*. 2017;9(10):1-13.
12. Sellers WFS. Asthma pressurised metered dose inhaler performance: propellant effect studies in delivery systems. *Allergy Asthma Clin Immunol*. 2017;13:30.
13. Adachi YS, Adachi Y, Itazawa T, Yamamoto J, Murakami G, Miyawaki T. Ability of preschool children to use dry powder inhalers as evaluated by In-Check Meter. *Pediatr Int*. 2006;48(1):62-65.
14. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. *Chest*. 2005;127(1):335-371.
15. Wilkinson AJK, Braggins R, Steinbach I, Smith J. Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England. *BMJ open*. 2019;9(10):e028763.
16. Janson C, Henderson R, Lofdahl M, Hedberg M, Sharma R, Wilkinson AJK. Carbon footprint impact of the choice of inhalers for asthma and COPD. *Thorax*. 2020;75(1):82-84.

It is made available under a [CC-BY-ND 4.0 International license](#) .